| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 77 | 2021 | 211 | 8.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2020 | 443 | 3.220 |
Why?
|
| Leukemia, Promyelocytic, Acute | 15 | 2018 | 20 | 2.470 |
Why?
|
| Mutation | 29 | 2020 | 497 | 2.040 |
Why?
|
| Antineoplastic Agents | 20 | 2018 | 595 | 1.300 |
Why?
|
| Middle Aged | 108 | 2020 | 11848 | 1.210 |
Why?
|
| MicroRNAs | 19 | 2017 | 181 | 1.140 |
Why?
|
| Prognosis | 52 | 2021 | 1534 | 1.140 |
Why?
|
| Cytarabine | 26 | 2019 | 59 | 1.090 |
Why?
|
| Aged | 86 | 2020 | 10260 | 1.090 |
Why?
|
| Female | 110 | 2020 | 19942 | 0.990 |
Why?
|
| Male | 108 | 2020 | 19437 | 0.960 |
Why?
|
| Adult | 81 | 2021 | 9256 | 0.960 |
Why?
|
| Treatment Outcome | 51 | 2020 | 3416 | 0.920 |
Why?
|
| Humans | 133 | 2021 | 32274 | 0.920 |
Why?
|
| Aged, 80 and over | 50 | 2020 | 3898 | 0.910 |
Why?
|
| Arsenicals | 6 | 2014 | 12 | 0.890 |
Why?
|
| Oxides | 6 | 2014 | 17 | 0.890 |
Why?
|
| Gene Expression Profiling | 22 | 2017 | 314 | 0.860 |
Why?
|
| Disease-Free Survival | 33 | 2020 | 324 | 0.840 |
Why?
|
| Young Adult | 36 | 2020 | 2648 | 0.840 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 335 | 0.800 |
Why?
|
| Remission Induction | 27 | 2018 | 92 | 0.710 |
Why?
|
| Leukemia, Myeloid | 12 | 2011 | 26 | 0.710 |
Why?
|
| Survival Rate | 29 | 2020 | 893 | 0.680 |
Why?
|
| Adolescent | 43 | 2020 | 3517 | 0.680 |
Why?
|
| Gene Expression Regulation, Leukemic | 12 | 2014 | 24 | 0.640 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2013 | 42 | 0.630 |
Why?
|
| Chromosome Aberrations | 7 | 2020 | 24 | 0.600 |
Why?
|
| Sulfides | 3 | 2019 | 27 | 0.600 |
Why?
|
| Caprylates | 3 | 2019 | 27 | 0.600 |
Why?
|
| Daunorubicin | 18 | 2018 | 27 | 0.600 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 11 | 2014 | 17 | 0.550 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2019 | 106 | 0.480 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 53 | 0.480 |
Why?
|
| Neoplasm Proteins | 12 | 2017 | 146 | 0.470 |
Why?
|
| Aorta, Thoracic | 1 | 2016 | 81 | 0.470 |
Why?
|
| Survival Analysis | 21 | 2016 | 477 | 0.470 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2020 | 105 | 0.440 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2011 | 18 | 0.440 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 39 | 0.420 |
Why?
|
| Karyotyping | 14 | 2020 | 27 | 0.420 |
Why?
|
| Tretinoin | 7 | 2018 | 33 | 0.410 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2017 | 25 | 0.410 |
Why?
|
| Translocation, Genetic | 5 | 2020 | 20 | 0.400 |
Why?
|
| Community Networks | 1 | 2013 | 22 | 0.390 |
Why?
|
| Developing Countries | 1 | 2013 | 57 | 0.380 |
Why?
|
| Resilience, Psychological | 1 | 2013 | 20 | 0.380 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2013 | 42 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2012 | 19 | 0.370 |
Why?
|
| Recurrence | 9 | 2021 | 285 | 0.370 |
Why?
|
| Drug Administration Schedule | 9 | 2018 | 276 | 0.360 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 5 | 2020 | 8 | 0.360 |
Why?
|
| Bone Marrow | 6 | 2020 | 68 | 0.350 |
Why?
|
| Salvage Therapy | 4 | 2019 | 135 | 0.340 |
Why?
|
| Prospective Studies | 9 | 2020 | 2316 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2018 | 64 | 0.320 |
Why?
|
| Burkitt Lymphoma | 3 | 2020 | 6 | 0.320 |
Why?
|
| Azacitidine | 4 | 2016 | 27 | 0.320 |
Why?
|
| Immunotoxins | 3 | 2007 | 18 | 0.320 |
Why?
|
| Age Factors | 15 | 2018 | 1179 | 0.310 |
Why?
|
| Neoplasm Staging | 6 | 2018 | 461 | 0.310 |
Why?
|
| Hospitalization | 2 | 2018 | 475 | 0.310 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 2240 | 0.310 |
Why?
|
| Cytogenetic Analysis | 11 | 2017 | 17 | 0.310 |
Why?
|
| Aminoglycosides | 3 | 2014 | 6 | 0.310 |
Why?
|
| Piperazines | 4 | 2011 | 60 | 0.310 |
Why?
|
| Pyrimidines | 4 | 2011 | 77 | 0.300 |
Why?
|
| Nuclear Proteins | 9 | 2021 | 74 | 0.300 |
Why?
|
| Cytogenetics | 6 | 2020 | 7 | 0.290 |
Why?
|
| Quality of Life | 2 | 2013 | 964 | 0.290 |
Why?
|
| Trisomy | 3 | 2019 | 11 | 0.280 |
Why?
|
| Risk Factors | 14 | 2020 | 3934 | 0.280 |
Why?
|
| Acute Disease | 14 | 2013 | 253 | 0.280 |
Why?
|
| Trans-Activators | 7 | 2011 | 43 | 0.280 |
Why?
|
| RNA, Neoplasm | 3 | 2014 | 18 | 0.270 |
Why?
|
| Interleukin-2 | 4 | 2013 | 38 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2019 | 15 | 0.270 |
Why?
|
| DNA-Binding Proteins | 6 | 2016 | 149 | 0.270 |
Why?
|
| DNA Mutational Analysis | 7 | 2017 | 69 | 0.260 |
Why?
|
| Etoposide | 11 | 2020 | 38 | 0.260 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 69 | 0.250 |
Why?
|
| Comorbidity | 5 | 2018 | 565 | 0.240 |
Why?
|
| Histone-Lysine N-Methyltransferase | 5 | 2020 | 27 | 0.240 |
Why?
|
| Diphtheria Toxin | 5 | 2003 | 28 | 0.240 |
Why?
|
| Mitoxantrone | 5 | 2019 | 20 | 0.230 |
Why?
|
| Time Factors | 10 | 2015 | 2204 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 381 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 245 | 0.230 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 81 | 0.230 |
Why?
|
| Neoplasms | 4 | 2019 | 754 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 821 | 0.220 |
Why?
|
| DNA Methylation | 3 | 2014 | 144 | 0.210 |
Why?
|
| Mitochondria | 2 | 2018 | 211 | 0.210 |
Why?
|
| Clinical Trials as Topic | 6 | 2017 | 312 | 0.210 |
Why?
|
| Methotrexate | 4 | 2014 | 70 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2013 | 160 | 0.200 |
Why?
|
| Phenotype | 4 | 2020 | 621 | 0.200 |
Why?
|
| DNA, Neoplasm | 4 | 2017 | 52 | 0.200 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 651 | 0.190 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2011 | 9 | 0.190 |
Why?
|
| Thalidomide | 2 | 2017 | 32 | 0.190 |
Why?
|
| Lymphocytosis | 1 | 2002 | 1 | 0.190 |
Why?
|
| Depression | 2 | 2016 | 420 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2016 | 18 | 0.180 |
Why?
|
| Genes, Wilms Tumor | 3 | 2010 | 6 | 0.170 |
Why?
|
| Cyclosporins | 4 | 2013 | 22 | 0.170 |
Why?
|
| Cognition | 2 | 2016 | 547 | 0.170 |
Why?
|
| Jacobsen Distal 11q Deletion Syndrome | 1 | 2020 | 1 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2019 | 8 | 0.160 |
Why?
|
| Proportional Hazards Models | 9 | 2015 | 773 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2009 | 48 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2017 | 1840 | 0.160 |
Why?
|
| Genes, Neoplasm | 2 | 2017 | 17 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2003 | 120 | 0.160 |
Why?
|
| Cell Line | 2 | 2018 | 454 | 0.160 |
Why?
|
| Tandem Repeat Sequences | 2 | 2012 | 7 | 0.160 |
Why?
|
| Retrospective Studies | 10 | 2018 | 3624 | 0.150 |
Why?
|
| Leukemia | 2 | 2014 | 38 | 0.150 |
Why?
|
| Uniparental Disomy | 1 | 2019 | 1 | 0.150 |
Why?
|
| Cell Membrane | 1 | 2020 | 109 | 0.150 |
Why?
|
| Loss of Heterozygosity | 1 | 2019 | 20 | 0.150 |
Why?
|
| Repressor Proteins | 3 | 2018 | 50 | 0.150 |
Why?
|
| Goals | 1 | 2019 | 34 | 0.150 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 9 | 0.150 |
Why?
|
| Gene Expression | 3 | 2012 | 345 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 883 | 0.140 |
Why?
|
| Chromosome Inversion | 3 | 2003 | 3 | 0.140 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 2 | 0.140 |
Why?
|
| North Carolina | 2 | 2013 | 1300 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2018 | 85 | 0.140 |
Why?
|
| Body Composition | 1 | 2020 | 327 | 0.140 |
Why?
|
| Communication | 1 | 2019 | 128 | 0.140 |
Why?
|
| Cell Respiration | 1 | 2018 | 20 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 258 | 0.140 |
Why?
|
| Genetic Loci | 1 | 2018 | 143 | 0.140 |
Why?
|
| Retreatment | 1 | 2018 | 42 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 179 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 83 | 0.130 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 13 | 0.130 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 4 | 2011 | 9 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2017 | 3 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 12 | 0.130 |
Why?
|
| Endothelial Growth Factors | 1 | 2017 | 12 | 0.130 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 141 | 0.130 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 5 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.130 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 97 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2017 | 53 | 0.130 |
Why?
|
| Biopsy | 1 | 2018 | 252 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cyclin D2 | 1 | 2016 | 7 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2011 | 38 | 0.130 |
Why?
|
| Codon | 1 | 2016 | 9 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2017 | 121 | 0.120 |
Why?
|
| WT1 Proteins | 3 | 2011 | 4 | 0.120 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2016 | 2 | 0.120 |
Why?
|
| Alleles | 4 | 2020 | 250 | 0.120 |
Why?
|
| Subclavian Artery | 1 | 2016 | 6 | 0.120 |
Why?
|
| Telomerase | 1 | 2016 | 20 | 0.120 |
Why?
|
| Diverticulum | 1 | 2016 | 11 | 0.120 |
Why?
|
| Vascular Malformations | 1 | 2016 | 11 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 179 | 0.120 |
Why?
|
| Aneurysm | 1 | 2016 | 20 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 423 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2018 | 484 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2017 | 95 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 729 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 179 | 0.120 |
Why?
|
| Naphthyridines | 1 | 2015 | 5 | 0.120 |
Why?
|
| Interferon-alpha | 3 | 2006 | 68 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 245 | 0.110 |
Why?
|
| Thiazoles | 1 | 2015 | 36 | 0.110 |
Why?
|
| Stem Cells | 2 | 2019 | 321 | 0.110 |
Why?
|
| Naphthalimides | 1 | 2015 | 1 | 0.110 |
Why?
|
| Mice | 2 | 2018 | 2571 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 219 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 189 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2004 | 16 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 24 | 0.110 |
Why?
|
| Polypharmacy | 1 | 2014 | 17 | 0.110 |
Why?
|
| Genotype | 4 | 2020 | 702 | 0.100 |
Why?
|
| Lymphoma | 1 | 2014 | 37 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 171 | 0.100 |
Why?
|
| Defense Mechanisms | 1 | 2013 | 4 | 0.100 |
Why?
|
| Sick Role | 1 | 2013 | 7 | 0.100 |
Why?
|
| Personality Inventory | 1 | 2013 | 15 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2013 | 15 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 100 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2013 | 20 | 0.100 |
Why?
|
| Culture | 1 | 2013 | 34 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 246 | 0.100 |
Why?
|
| Disease Progression | 4 | 2017 | 591 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2017 | 15 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2011 | 308 | 0.100 |
Why?
|
| Animals | 5 | 2018 | 8199 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 73 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 2 | 2017 | 27 | 0.090 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 7 | 0.090 |
Why?
|
| Asparaginase | 2 | 2015 | 5 | 0.090 |
Why?
|
| Leukemia, B-Cell | 2 | 2002 | 5 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 1050 | 0.090 |
Why?
|
| Psychometrics | 1 | 2013 | 137 | 0.090 |
Why?
|
| Logistic Models | 5 | 2015 | 743 | 0.090 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 264 | 0.090 |
Why?
|
| Infant | 4 | 2018 | 1010 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2009 | 7 | 0.090 |
Why?
|
| Panax | 1 | 2012 | 9 | 0.090 |
Why?
|
| Obesity | 2 | 2017 | 1111 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2019 | 24 | 0.090 |
Why?
|
| Blast Crisis | 1 | 2011 | 4 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 131 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 161 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2013 | 135 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2011 | 12 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 40 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2018 | 1233 | 0.090 |
Why?
|
| Leukocyte Count | 3 | 2017 | 46 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 3 | 2017 | 96 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2012 | 61 | 0.090 |
Why?
|
| Up-Regulation | 4 | 2017 | 193 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 555 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 757 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 332 | 0.080 |
Why?
|
| Gene Duplication | 1 | 2010 | 5 | 0.080 |
Why?
|
| North America | 1 | 2010 | 31 | 0.080 |
Why?
|
| Cyclophosphamide | 4 | 2020 | 37 | 0.080 |
Why?
|
| Child | 5 | 2018 | 2434 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2011 | 242 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2012 | 1425 | 0.080 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2010 | 7 | 0.080 |
Why?
|
| Drug Resistance, Multiple | 3 | 2008 | 7 | 0.080 |
Why?
|
| Benzamides | 4 | 2011 | 60 | 0.080 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 907 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2007 | 56 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 186 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2012 | 30 | 0.070 |
Why?
|
| Topotecan | 1 | 2009 | 14 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 34 | 0.070 |
Why?
|
| Leukocytosis | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 1158 | 0.070 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2007 | 1 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2009 | 43 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 20 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1437 | 0.060 |
Why?
|
| Asparagine | 1 | 2007 | 6 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 132 | 0.060 |
Why?
|
| Transplantation, Homologous | 3 | 2015 | 158 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 63 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 97 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 11 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2007 | 46 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2017 | 499 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2018 | 666 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2004 | 6 | 0.050 |
Why?
|
| Anemia, Refractory | 1 | 2004 | 2 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 717 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2004 | 59 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2004 | 5 | 0.050 |
Why?
|
| Fever of Unknown Origin | 1 | 2004 | 10 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2017 | 854 | 0.050 |
Why?
|
| Exanthema | 1 | 2004 | 19 | 0.050 |
Why?
|
| Vidarabine | 1 | 2003 | 6 | 0.050 |
Why?
|
| Ergocalciferols | 1 | 2003 | 3 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2002 | 3 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2008 | 128 | 0.050 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2002 | 1 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2002 | 15 | 0.050 |
Why?
|
| Monosomy | 1 | 2002 | 5 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2002 | 21 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 28 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2015 | 565 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 78 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 26 | 0.050 |
Why?
|
| Chromosome Disorders | 1 | 2002 | 1 | 0.050 |
Why?
|
| Anemia, Aplastic | 1 | 2002 | 4 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 79 | 0.040 |
Why?
|
| Compassionate Use Trials | 2 | 2011 | 3 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 68 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 2013 | 100 | 0.040 |
Why?
|
| Survivors | 2 | 2016 | 173 | 0.040 |
Why?
|
| Apoptosis | 1 | 2003 | 375 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 12 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 502 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 211 | 0.040 |
Why?
|
| Vincristine | 1 | 2020 | 24 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 146 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 69 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 76 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 10 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2011 | 200 | 0.040 |
Why?
|
| Comprehension | 1 | 2019 | 19 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 15 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2016 | 461 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 129 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 112 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 292 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 3 | 0.030 |
Why?
|
| Angiogenic Proteins | 1 | 2017 | 10 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 22 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 189 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 26 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2017 | 41 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 90 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 543 | 0.030 |
Why?
|
| Proteins | 1 | 2017 | 149 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 86 | 0.030 |
Why?
|
| RNA | 1 | 2016 | 94 | 0.030 |
Why?
|
| Body Surface Area | 1 | 2015 | 15 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2008 | 124 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 111 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 390 | 0.030 |
Why?
|
| Aziridines | 2 | 2005 | 3 | 0.030 |
Why?
|
| Benzoquinones | 2 | 2005 | 5 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 204 | 0.030 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 2 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 6 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2016 | 183 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 208 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 603 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 28 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 20 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 54 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 52 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 23 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 4 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 23 | 0.030 |
Why?
|
| Receptors, CXCR | 1 | 2013 | 3 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 15 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 126 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1076 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 505 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 90 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 305 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 109 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2003 | 12 | 0.020 |
Why?
|
| United States | 2 | 2012 | 4072 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2012 | 9 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 5 | 0.020 |
Why?
|
| Peripheral Nervous System | 1 | 2012 | 5 | 0.020 |
Why?
|
| Pyrazines | 1 | 2012 | 14 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 13 | 0.020 |
Why?
|
| Cell Division | 2 | 2003 | 92 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 66 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 863 | 0.020 |
Why?
|
| F-Box Proteins | 1 | 2012 | 3 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Injections, Subcutaneous | 2 | 2002 | 36 | 0.020 |
Why?
|
| Bone Marrow Cells | 2 | 2003 | 114 | 0.020 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2011 | 21 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 52 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 222 | 0.020 |
Why?
|
| African Americans | 1 | 2017 | 1335 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 853 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 83 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 130 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 49 | 0.020 |
Why?
|
| Diarrhea | 1 | 2009 | 56 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 324 | 0.020 |
Why?
|
| Ideal Body Weight | 1 | 2009 | 6 | 0.020 |
Why?
|
| Fatigue | 1 | 2009 | 76 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 14 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 48 | 0.020 |
Why?
|
| Busulfan | 1 | 2008 | 6 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1241 | 0.020 |
Why?
|
| RNA Probes | 1 | 2008 | 4 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 6 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2007 | 13 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2008 | 91 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 471 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2005 | 3 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2007 | 221 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 26 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 6 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2003 | 14 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2003 | 22 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 74 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2002 | 4 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 17 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2003 | 75 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 942 | 0.010 |
Why?
|
| Bacillus anthracis | 1 | 2002 | 8 | 0.010 |
Why?
|
| Thymidine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2002 | 5 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2002 | 28 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2002 | 29 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 144 | 0.010 |
Why?
|
| Hypocalcemia | 1 | 2002 | 14 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2002 | 47 | 0.010 |
Why?
|
| Liver Failure | 1 | 2002 | 21 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 94 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 164 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 290 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 359 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2002 | 204 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2002 | 57 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 104 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 165 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 553 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 237 | 0.010 |
Why?
|